0RC6.LSE Pharma Mar SAU
- Market cap
- EUR 16.4B
- P/E
- 14.7x
- P/B
- -
- ROE
- 2.5%
- Dividend yield
- 1.19%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.
Is 0RC6.LSE undervalued?
Graham numberThe Graham number of Pharma Mar SAU cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pharma Mar SAU fundamental analysis
No fundamental analysis for Pharma Mar SAU yet.
Pharma Mar SAU stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pharma Mar SAU
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue…
Full company profilePharma Mar SAU financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pharma Mar SAU annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 181M | 159M | 109M | 85.8M | 270M | 230M | 196M | 158M | 175M | 221M | 172M |
| Gross Profit | 137M | 124M | 104M | 80.6M | 256M | 213M | 183M | 149M | 167M | 209M | 157M |
| Operating Income | -18.7M | -19.5M | -16.0M | -17.5M | 157M | 92.4M | 42.1M | -3.83M | 6.47M | 40.3M | 2.49M |
| EBITDA | -15.3M | -16.2M | -13.4M | -15.2M | 159M | 95.0M | 44.9M | -1.15M | 21.2M | 48.3M | 10.8M |
| Net Income | -24.1M | -28.2M | -17.1M | -9.16M | 137M | 92.9M | 49.4M | 1.14M | 26.1M | 75.0M | 6.13M |
| EPS | -1.31 | -1.53 | -0.93 | -0.50 | 7.49 | 5.13 | 2.73 | 0.06 | 1.49 | 4.36 | 0.36 |
| Balance Sheet | |||||||||||
| Total Assets | 221M | 188M | 158M | 125M | 330M | 368M | 393M | 341M | 350M | 395M | 385M |
| Total Liabilities | 173M | 165M | 140M | 117M | 228M | 190M | 170M | 147M | 141M | 143M | 136M |
| Shareholders' Equity | 52.4M | 26.9M | 21.4M | 11.4M | 103M | 178M | 223M | 193M | 208M | 252M | 250M |
| Cash & Short-term Investments | 32.4M | 31.8M | 26.9M | 20.9M | 196M | 202M | 182M | 163M | 155M | 167M | 168M |
| Total Debt | 95.5M | 99.8M | 93.4M | 84.4M | 55.2M | 47.5M | 41.0M | 41.7M | 51.1M | 49.4M | 47.5M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -8.41M | -1.46M | -16.8M | -24.2M | 279M | 25.7M | 38.3M | -13.4M | 6.03M | 53.1M | - |
| Capital Expenditure | 6.09M | 3.51M | 1.89M | 3.96M | 3.00M | 7.80M | 8.85M | 16.0M | 15.5M | 9.38M | 2.70M |
| Free Cash Flow | -14.5M | -4.97M | -18.7M | -28.2M | 276M | 17.9M | 29.5M | -29.4M | -9.48M | 43.8M | - |
| Ratios | |||||||||||
| ROE | -46.0% | -104.9% | -79.9% | -80.6% | 133.6% | 52.2% | 22.1% | 0.6% | 12.5% | 29.8% | 2.5% |
| ROA | -10.9% | -15.0% | -10.8% | -7.3% | 41.6% | 25.2% | 12.6% | 0.3% | 7.5% | 19.0% | 1.6% |
| Net Profit Margin | -13.3% | -17.7% | -15.7% | -10.7% | 50.8% | 40.4% | 25.1% | 0.7% | 14.9% | 33.9% | 3.6% |
| Debt to Equity | 1.82x | 3.72x | 4.37x | 7.42x | 0.54x | 0.27x | 0.18x | 0.22x | 0.25x | 0.20x | 0.19x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Pharma Mar SAU dividends
- Dividend yield
- 1.19%
- Forward dividend
- -
- Payout ratio
- 18.6%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | 13.9M | 0.81 | 18.6% |
| 2024 | EUR 11.4M | 0.65 | 43.7% |
| 2023 | EUR 11.7M | 0.65 | 1,028.1% |
| 2022 | EUR 11.8M | 0.65 | 23.8% |
| 2021 | EUR 10.9M | 0.60 | 11.7% |
| 2020 | EUR 8.82M | 0.48 | 6.4% |
| 2019 | EUR 8.82M | 0.48 | - |
| 2018 | EUR 8.82M | 0.48 | - |
| 2017 | EUR 19.9M | 1.08 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 0.083333:1 on Jul 22, 2020.
Who owns Pharma Mar SAU
- Insiders 27.21%
- Institutions 10.85%
- Public & others 61.94%
- Shares outstanding 221M
- Free float 13.4M
Pharma Mar SAU company profile
- Company name
- Pharma Mar SAU
- Ticker
- 0RC6.LSE
- ISIN
- ES0169501022
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 505
- Fiscal year end
- December
- Address
- Avenida de los Reyes, 1, Madrid, Spain, 28770
- Phone
- 34 91 846 60 00
- Website
- pharmamar.com
About Pharma Mar SAU
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue sarcoma and ovarian cancer; Zepzelca, a synthetic compound designed to treat small lung cancer cells; and Aplidin, that is extracted from the ascidian Aplidium albicans to treat patients with multiple myeloma. It also develops LAGOON, which is in Phase III clinical trial for the treatment of small cell lung cancer; SaLuDo, which is in Phase III trial to treat patients with metastatic leiomyosarcoma; as well as PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; and SYL1801 that is in phase II clinical trials for treating and preventing choroidal neovascularization, such as age-related macular degeneration (AMD) and diabetic retinopathy. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.
Pharma Mar SAU management
10- Mr. Jose Maria Fernandez Sousa-Faro Ph.D.Founder, Executive Chairman, CEO & President
- Mr. Pedro Francisco Fernandez PuentesExecutive Vice-Chairman
- Mr. Juan Carlos-Torres CarreteroFounder · born 1949
- Ms. María Luisa de Francia CaballeroChief Financial Officer
- Mr. José Luis Moreno Martinez-LosaHead of Capital Markets & Investor Relations
- Mr. Juan Gomez PulidoGeneral Counsel & Secretary of the Board of Directors
- Ms. Sandra Llamera SanchezGlobal Compliance Head
- Ms. Lara VadilloCommunication Director
- Ms. Belén Sopesén Veramendi Ph.D.Director of Corporate Development
- Mr. Luis Rupérez CuencaDirector of Human Resources & IT